Logo

Chris Connelly, Brad Hunsley, Carissa Moore, Subodh Nimkar, John Scholl

Nov 13, 2017

Streck announced five new members of its leadership team: 

  • Chris Connelly, director of R&D for new product development/molecular. Connelly joined Streck in 2010 and was previously R&D scientific manager for the molecular division. 
  • Brad Hunsley, director of R&D for application development/existing products. Hunsley joined Streck in 1989, has held various leadership positions, and is currently a member of the company's scientific advisory committee.
  • Carissa Moore, director of R&D for new product development/stabilization and flow cytometry. Moore joined Streck in 2011 as an R&D scientist, and she served as R&D scientific manager from 2016 to 2017.
  • Subodh Nimkar, director of strategic marketing. Nimkar most recently served as a North America marketing programs manager at Agilent Technologies.
  • John Scholl, director of R&D for application development/private label products. Scholl joined Streck's R&D department in 1987 as a technician and was promoted to various supervisory positions in the department.
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.